TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Complexa raises $13M to fund trials of kidney disease drug

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

Daily Photo Galleries

Business Photo Galleries

Wednesday, June 4, 2014, 10:51 a.m.
 

Complexa Inc., a South Side-based drug development company, said it raised $13 million from investors that will fund clinical trials of a drug to treat kidney disease.

The funding round, Complexa's second, was led by Jafco Life Science Investment, an arm of Japanese private equity firm Jafco Co. Ltd.

The company previously raised more than $8 million from venture capital investors to license and develop molecules discovered and patented by professor Bruce Freeman and a team of researchers at the University of Pittsburgh.

There is “great interest” in Complexa's work from large pharmaceutical companies, Jafco officials said in a statement.

Add Alex Nixon to your Google+ circles.

Subscribe today! Click here for our subscription offers.

 

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Few in Westmoreland County opposed to expansion plan for Mariner pipeline
  2. Rue21 adjusts for tough market
  3. Oilfield employee cutbacks may benefit long-haul trucking
  4. Whistle-blower incentives advance
  5. Western Pa. builders earn top honors for work
  6. Refinery turbulence drives up pump prices
  7. Rocket firm hired to probe deadly air bags
  8. Make me a match: Fidelity to match some IRA contributions
  9. Giant Eagle to close all 8 Good Cents locations
  10. Oil stocks drag on Dow, S&P 500; Nasdaq moves closer to record
  11. Dockworkers begin clearing backed-up cargo from West Coast seaports